OBJECTIVES: Multiple organ failure in critically ill patients is associated with poor prognosis, but biomarkers contributory to pathogenesis are unknown. Previous studies support a role for Fas cell surface death receptor (Fas)-mediated apoptosis in organ dysfunction. Our objectives were to test for associations between soluble Fas and multiple organ failure, identify protein quantitative trait loci, and determine associations between genetic variants and multiple organ failure.

DESIGN: Retrospective observational cohort study.

SETTING: Four academic ICUs at U.S. hospitals.

PATIENTS: Genetic analyses were completed in a discovery (n = 1,589) and validation set (n = 863). Fas gene expression and flow cytometry studies were completed in outpatient research participants (n = 250).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: In discovery and validation sets of critically ill patients, we tested for associations between enrollment plasma soluble Fas concentrations and Sequential Organ Failure Assessment score on day 3. We conducted a genome-wide association study of plasma soluble Fas (discovery n = 1,042) and carried forward a single nucleotide variant in the FAS gene, rs982764, for validation (n = 863). We further tested whether the single nucleotide variant in FAS (rs982764) was associated with Sequential Organ Failure Assessment score, FAS transcriptional isoforms, and Fas cell surface expression.

Higher plasma soluble Fas was associated with higher day 3 Sequential Organ Failure Assessment scores in both the discovery (β = 4.07; p < 0.001) and validation (β = 6.96; p < 0.001) sets. A single nucleotide variant in FAS (rs982764G) was associated with lower plasma soluble Fas concentrations and lower day 3 Sequential Organ Failure Assessment score in meta-analysis (−0.21; p = 0.02). Single nucleotide variant rs982764G was also associated with a lower relative expression of the transcript for soluble as opposed to transmembrane Fas and higher cell surface expression of Fas on CD4+ T cells.

CONCLUSIONS: We found that single nucleotide variant rs982764G was associated with lower plasma soluble Fas concentrations in a discovery and validation population, and single nucleotide variant rs982764G was also associated with lower organ dysfunction on day 3. These findings support further study of the Fas pathway as a potential mediator of organ dysfunction in critically ill patients.

KEY WORDS: Fas cell surface death receptor (Fas, CD95); organ dysfunction scores; quantitative trait loci; single nucleotide variant; sepsis; soluble Fas
to excessive apoptosis, or programmed cell death, has been implicated in the development of organ failure in the ICU, including acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), sepsis, and multiple organ dysfunction syndrome (4–7).

Fas is a type 1 membrane receptor, which mediates apoptosis through binding Fas ligand (FasL) (8). Soluble Fas (sFas) is a truncated form of Fas believed to result from alternative messenger RNA (mRNA) splicing through skipping of exon 6 of FAS that encodes the transmembrane domain (9–12). The Fas pathway is thought to affect both immune modulation via apoptosis of leukocytes and end-organ damage via apoptosis of epithelial cells (13–16). Observational studies have shown that higher levels of sFas are associated with poor outcomes in ARDS (4, 17, 18). Studies in critically ill cohorts have shown that common genetic polymorphisms in the FAS/FASL-related genes are associated with ARDS susceptibility and development of AKI in ICU populations (19, 20). Thus, previous association studies show a link between the Fas/FasL system and organ dysfunction. However, protein quantitative trait loci (pQTL) for sFas have not been identified. If these loci are discovered, associations between them and multiple organ dysfunction could be used for future causal analyses between sFas and organ dysfunction.

In this study, we conducted a genome-wide association study (GWAS) in a multicenter discovery set to determine single nucleotide variants (SNVs) associated with sFas levels. Then, using the strongest candidate SNV within the FAS gene, we tested the hypothesis that lower sFas concentrations are associated with organ dysfunction in the ICU, as measured by Sequential Organ Failure Assessment (SOFA) score on day 3 (21). We then replicated our findings in an external validation set.

**MATERIALS AND METHODS**

Detailed methods are available in the Supplemental Methods (http://links.lww.com/CCM/G857).

Discovery set (Identification of SNPs Predisposing to Altered ALI Risk [iSPAAR] consortium). Subjects (n = 1,589) were all critically ill with genome-wide genotyping data and clinical variables that are publicly available (22). The parent study included only Caucasian subjects to reduce confounding due to population stratification. For a subset of subjects (n = 1,042), plasma was obtained within 48 hours of enrollment. For a partially overlapping subset of patients (n = 1,072), an adjusted SOFA score (21) excluding the Glasgow Coma Scale (GCS) component was available (Fig. S1, http://links.lww.com/CCM/G857).

Validation set (Harborview Medical Center systemic inflammatory response syndrome [SIRS]). Critically ill patients (n = 863) were prospectively enrolled after meeting criteria for the SIRS (23). Subjects were Caucasian, and blood was obtained within 24 hours of ICU admission. All subjects had a SOFA score, and the GCS component was excluded to match the discovery set.

Our primary outcome measurement was day 3 SOFA score without the GCS component in subjects who survived to day 3. We chose this outcome because we hypothesized, given prior findings, that sFas might participate in altering risk for organ dysfunction such as respiratory and renal failure. We chose a time point that occurred after plasma sample acquisition but relatively proximal to the sampling to minimize noise from secondary events and interventions.

**Genotyping**

Discovery subjects were genotyped using the Illumina Human 660W-Quad BeadChip (San Diego, CA). We removed SNVs with a minor allele frequency less than 0.03, an overall call rate less than 90%, and for deviation from Hardy-Weinberg Equilibrium (p < 0.001) (24). This resulted in 488,966 SNVs. Imputation was performed via the Michigan Imputation Server with 1000 Genomes Project phase 3 data as the reference panel (25, 26). We additionally analyzed imputed SNVs within 10 kB of the 5′ and 3′ end of the FAS gene. Validation subjects were genotyped for the SNP rs982764 by Taqman polymerase chain reaction (PCR) (ThermoFisher Scientific, Waltham, MA).

**Plasma sFas Measurements**

We measured plasma sFas protein concentrations using an antibody-based assay (Meso Scale Discovery, Gaithersburg, MD).

**Quantitative Reverse Transcriptase PCR**

Healthy subject mRNA cohort: We recruited healthy subjects, and genotyping was performed on the Illumina Human 1M beadchip array (San Diego, CA) (27). RNA was purified from unstimulated whole blood. We selectively performed SYBR green quantitative
reverse transcriptase PCR in all subjects homozygous for the minor allele rs982764G (n = 17), heterozygotes (n = 20), and major allele homozygotes (n = 25). Two distinct forward primers were used for the isoforms containing exon 6 (membrane Fas) and for skipping exon 6 (sFas). The same reverse primer was used for both isoforms. The relative expression of sFas to Fas was calculated as 2−(ΔΔCt sFas−Fas).

Flow Cytometry

Benaroya Research Institute (BRI) cohort: Subjects (n = 188) were genotyped on the Illumina ImmunoChip (San Diego, CA). Subjects were healthy or had diabetes. Peripheral blood mononuclear cells were stained with fluorophore-conjugated monoclonal antibodies against CD3, CD8, CD4, CD45RA, CD19, CD62L, and Fas (CD95) (28–30). Hierarchical gating schemes are shown in Figure S2 (http://links.lww.com/CCM/G857).

Data Analysis

In the discovery and validation sets, we tested for associations between log10-transformed sFas concentration and day 3 SOFA without GCS in subjects who survived to day 3 by multivariate linear regression adjusting for age, gender, and sepsis (sepsis-2 definition).

In the discovery GWAS, we used linear regression to test for associations with each variant and log10-transformed plasma sFas concentration, using an additive model adjusting for age, gender, sepsis, and the first three principal components of ancestry (PCAs). In the validation phase, we tested for associations between rs982764 and log10-transformed plasma sFas concentration adjusting for age, gender, and sepsis. We did not adjust for PCAs as no genome-wide data are available for this set. Genetic association testing was performed using Golden Helix SNP & Variation Suite (Bozeman, MT).

We further tested for associations between rs982764 genotype and sFas threshold cycle (Ct)/Fas Ct ratio in the healthy subject mRNA cohort and median florescent intensity of Fas on memory CD4+ T cells, B cells, or CD8+ long-term effector memory cells in the Benaroya Research Cohort. Linear regression analysis using an additive genetic model were performed using Stata 14 (Stata LP, College Station, TX). Except for the GWAS (significant p < 1 × 10−6), a p value of less than 0.05 was considered significant.

All studies were approved by human subject committees at the respective institutions (University of Washington institutional review board [IRB] number 1389, 3181, 37361 and BRI IRB number 07109).

RESULTS

Subjects in both the discovery and validation were predominantly male (58% and 63%, respectively) and middle aged (mean age 58 ± 17 and 55 ± 16) (Table 1). Sepsis was the predominant form of critical illness (76% and 71%, respectively). Subjects in the discovery set were on average more severely ill at admission than the validation set (mean Acute Physiology and Chronic Health Evaluation III score of 78 and 65, respectively). Subjects in the discovery set had a higher proportion of ARDS (64%) and higher persistent systemic organ dysfunction (mean day 3 SOFA of 5). Clinical characteristics of subjects within each area of the Venn diagram shown in Figure S1 (http://links.lww.com/CCM/G857) (i.e., genotyped, plasma sFas only, SOFA only) were similar (Table S1, http://links.lww.com/CCM/G857).

The mean (± sd) plasma sFas concentrations were 11,082 (± 7,265) pg/mL and 13,419 (± 7,670) pg/mL in the discovery and validation sets, respectively.

Plasma sFas and Organ Dysfunction

In the discovery set, we found that a one log10 unit increase in plasma sFas concentration was associated with a 4.40 point (95% CI, 3.53–5.28; p < 0.001) higher day 3 SOFA score (Table 2). This finding was also seen in the validation set, with one log10 unit change in sFas concentrations associated with a 6.96 point (95% CI, 5.95–7.97; p < 0.001) (Table 2) higher day 3 SOFA score. Plasma sFas was broadly associated with higher organ dysfunction including coagulation (Fig. 1A), renal (Fig. 1B), and liver (Fig. 1C), cardiovascular (Fig. S3, http://links.lww.com/CCM/G857), in both the discovery and validation sets (Fig. 1D–F). (Fig. S3, http://links.lww.com/CCM/G857) (all p < 0.001). Respiratory organ dysfunction was not associated with higher sFas level in the discovery set (Fig. S3, http://links.lww.com/CCM/G857) (p = 0.06), possibly due to the fact the degree of respiratory dysfunction was skewed toward higher values in this group. These results demonstrate robust associations between higher plasma sFas and higher systemic organ dysfunction in critically ill patients.
### TABLE 2.
Multivariate Analysis of Soluble Fas Association With Sequential Organ Failure Assessment Score

<table>
<thead>
<tr>
<th>Soluble Fas (log10 [pg/mL])</th>
<th>n</th>
<th>Unadjusted β (95% CI)</th>
<th>p</th>
<th>Adjusted β* (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery</td>
<td>525</td>
<td>4.40 (3.53–5.28)</td>
<td>&lt; 0.001</td>
<td>4.07 (3.13–5.01)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Validation</td>
<td>579</td>
<td>7.11 (6.10–8.12)</td>
<td>&lt; 0.001</td>
<td>6.96 (5.95–7.97)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*Adjusted for age, gender, and sepsis.

### SNVs and Plasma sFas

No SNV reached genome-wide significance in the GWAS of plasma sFas levels in the discovery set ([Table S2,](http://links.lww.com/CCM/G857)). The quantile-quantile plot did not suggest residual confounding ([Fig. S4,](http://links.lww.com/CCM/G857)). Although not genome-wide significant, one of the strongest associations was observed with an SNV located within an intron of ***FAS*** (rs982764; \( p = 1.81 \times 10^{-5} \)) ([Fig. S5,](http://links.lww.com/CCM/G857)). The minor allele for rs982764 was associated with lower sFas levels (additive model, \( \hat{\beta} = -0.05 \)) ([Fig. 2A](http://links.lww.com/CCM/G857)). The SNV with the strongest association with sFas levels was rs11663956 in ***LAMA1***, encoding Laminin α1 ([Table S2,](http://links.lww.com/CCM/G857)). The third most highly associated SNV (rs820371; \( p = 5.6 \times 10^{-6} \)) was located within an intron of ***MYLK***.

We focused on the variants within the ***FAS*** gene given that these variants could represent cis-pQTL and, thus, have high biologic plausibility. We sought to more finely map the peak association within ***FAS*** using densely imputed SNVs, but the peak of association remained at rs982764 ([Fig. S6,](http://links.lww.com/CCM/G857)). An imputed, intronic SNV was equivalently associated (rs7911226) and was in perfect linkage disequilibrium (\( R^2 = 1.0; D' = 1.0 \)) with rs982764.

In a sensitivity analysis limiting to subjects with sepsis...
(n = 681), rs982764 remained associated with lower plasma concentrations (log_{10}-transformed) of sFas (β = −0.05; 95% CI, −0.03 to −0.07; \( p = 2.47 \times 10^{-4} \)). Similarly, in the validation set, each copy of the minor allele was associated with lower plasma sFas (β = −0.04; \( p = 0.009 \)) (Fig. 2B).

**SNV and Organ Dysfunction**

We then tested for associations between rs982764 and organ dysfunction. We found that in an additive model that the minor allele (G) of rs982764 trended toward lower day 3 SOFA score in both the
SNV, Alternative Splicing, and Fas Cell Surface Expression

We wanted to test splice variation as a potential mechanism for the association between rs982764 and plasma sFas and used two additional cohorts with mRNA and flow cytometry data available. First, we tested whether rs982764 was associated with differences in FAS mRNA isoform proportions. Differential expression of FAS mRNA splice variants due to rs982764 could lead to differences in sFas production. We used PCR assays to detect FAS mRNA splice variants with exon 6 (exon 5-6-7) or that skip exon 6 (exon 5-7, skip 6). Exon 6 is the region encoding the transmembrane domain, and exclusion of exon 6 is thought to produce the soluble form of Fas (sFas) (9, 10). We compared the relative expression of the two isoforms by rs982764 genotype in mRNA from whole blood obtained

Figure 2. rs982764 and relationship to Fas. Genotype rs982763G is associated with lower plasma soluble Fas (sFas) in the discovery (A) and validation (B) sets. Number of subjects of each rs982764 genotype (AA, AG, GG) is shown on the x-axis. Whiskers extend from 10th to 90th percent value, and box ranged from the 25th to 75th percentile with line at the median. p value represents multiple linear regression adjusted for age, gender, and sepsis using an additive genetic model. C, RNA was collected from unstimulated whole blood samples from healthy controls of differing genotype. Quantitative reverse transcriptase-polymerase chain reaction RNA was performed for transcripts containing exon 6 (membrane bound “Fas”) and skipping exon 6 (sFas). The relative expression of sFas to Fas was calculated as $2^{-\Delta\text{Ct Fas-sFas}}$. Median florescent intensity (MFI) of cell surface FAS on memory CD4+ T cells (D), B cells (E), and long-term effector memory (LTEM) CD8+ T cells (F). p values are for linear regression using an additive genetic model $\Delta\text{Ct} =$ difference in cycle threshold values.
from a cohort of healthy subjects. We found that the minor allele of rs982764 was associated with lower relative expression of the isoform that excludes exon 6 (p < 0.05) (Fig. 2C) which supports the hypothesis that the G allele of rs982764 reduces sFas production through altered RNA splicing.

Next, we tested whether the minor allele of rs982764 was associated with cell surface expression of Fas in a second cohort of subjects with available flow cytometry data for circulating leukocytes. We found that surface expression of Fas measured by mean florescent intensity (MFI) was higher on CD4+ T cells for each copy of the minor allele of rs982764 (Fig. 2D). These findings provide further support for the hypothesis that the minor allele of rs982764 leads to lower circulating sFas through altered isoform ratios favoring production of transmembrane Fas. We did not observe a significant difference in cell surface Fas expression on B cells and long-term effector memory CD8+ T cells by rs982764 genotype (Fig. 2, E and F, respectively).

**DISCUSSION**

Our studies extend prior work demonstrating a strong association between higher circulating sFas and more severe organ dysfunction in critically ill patients and provide the first evidence of a quantitative trait loci (QTL) for plasma levels of sFas in acute critical illness. We showed that this QTL is marked by rs982764, a SNV located in the intron 4-5 in FAS. It is associated with both decreased levels of plasma sFas and lower levels of organ failure in meta-analyses in these cohorts. These findings provide evidence supporting associations between sFas and organ failure in critically ill patients.

Our findings that higher plasma sFas is associated with increased organ dysfunction as measured by SOFA score is consistent with previous studies of AKI, ARDS, and multiple organ dysfunction syndrome (18–20, 31). We have previously shown that sFas concentrations are associated with a distinct form of nonresolving AKI in studies that employed the set used here for validation (32). Although we observed robust associations between sFas and organ dysfunction in both the discovery and validation sets, we did not find an association between sFas and respiratory failure in the discovery set. This exception is notable given our own work showing that other genetic variants in FAS associate with risk for ARDS (19). These previously published variants in FAS were not associated with lung injury in this discovery cohort. We postulate that our finding in the discovery set could be due to the very different overall proportion of subjects with severe respiratory failure at the time of enrollment and, thus, potential differences in timing of sample acquisition relative to onset of organ failure. Future studies will need to clarify the temporal relationship between the onset of the cause of critical illness (e.g., pneumonia, trauma) and sFas levels and, in turn, organ failure onset.

Our finding that the variants within FAS are strongly associated with circulating sFas levels in two critically ill cohorts provides very strong evidence that this locus is a true QTL for sFas production. Prior evidence from patients with coronary artery disease suggests that rs982764 may be a QTL for sFas in the population more generally (33) although this is the first report that suggests a link between genetic modulation of sFas levels and risk for a clinical outcome. We also provide new evidence that this QTL may influence sFas levels through altered levels of FAS mRNA isoforms. There is insufficient evidence to explain how sFas levels might affect organ dysfunction or whether the effect might be more directly related to altered CD4+ T-cell expression.

### Table 3.

**Association of rs982764 With Sequential Organ Failure Assessment Score**

<table>
<thead>
<tr>
<th>Subject Set</th>
<th>n</th>
<th>β (95% CI)a</th>
<th>p</th>
<th>Adjusted β (95% CI)b</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery</td>
<td>1,072</td>
<td>–0.24 (–0.48 to 0.02)</td>
<td>0.07</td>
<td>–0.25 (–0.49 to 0.00)</td>
<td>0.06</td>
</tr>
<tr>
<td>Validation</td>
<td>861</td>
<td>–0.18 (–0.45 to 0.10)</td>
<td>0.21</td>
<td>–0.18 (–0.45 to 0.10)</td>
<td>0.20</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td></td>
<td>–0.21 (–0.39 to –0.02)</td>
<td>0.03</td>
<td>–0.21 (–0.40 to –0.03)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

a Effect size and direction for change in mean Sequential Organ Failure Assessment for each copy of minor allele of rs982764 (allele A>allele G).

b Adjusted for age, gender, and sepsis.
of Fas and modulation of immune cell apoptosis. Our findings with this variant are supported by strong biological plausibility due to the “cis” location and the effect on relevant mRNA isoforms; however, it only explains 1.6% of the variance in plasma sFas levels. Future work will need to clarify the other major factors (e.g., demographic, environmental) influencing sFas levels.

Although no SNV reached genome-wide significance in our discovery phase, variants in genes other than FAS also showed highly suggestive associations with sFas levels including variants within myosin light chain kinase (MYLK), a gene previously associated with risk for ARDS (34, 35). Notably, myosin light chain kinase enzyme activity is also linked to cellular apoptosis (36). The SNV most strongly associated with sFas levels was located in LAMA1, a gene implicated in organ development and shown to modulate the pulmonary response to lung injury and fibrosis, biologic processes relevant to acute organ dysfunction (37). Future work will need to clarify whether these loci might be true “trans” QTL for sFas levels and whether these loci affect clinical outcomes in which Fas-mediated cell death is pathophysiologically relevant.

Our study has several limitations. First, a significant proportion of the subjects in the discovery set were enrolled through interventional clinical trials, and all patients were recruited at academic medical centers which may limit the generalizability of our results. Second, we limited this study to Caucasian subjects only in an effort to reduce the potential confounding effects of population stratification. Future work will need to determine whether our findings are relevant to more diverse populations. Third, testing associations with SOFA scores on days other than day 3 would have been informative, but some missing data and timing differences between the datasets prevented us performing these analyses. Fourth, our findings of an association between rs982764 and organ failure were marginal when tested in the discovery and validation sets individually while showing a significant association in the meta-analysis. Our estimates from this study suggest that sample sizes of greater than 3,000 subjects would be necessary to fully power future studies. Although this finding will need to be further replicated, the fact that the direction of effect was consistent in the two independent cohorts provides some reassurance as to its validity. Finally, we did not have access to any critically ill study populations that had simultaneous measures of genotype, gene expression, plasma protein measurements, and clinical outcomes. However, the consistency of the direction of effects observed with the G allele of rs982764 G in the different study groups (i.e., reduced exon 6–negative mRNA isoform, increased cell surface Fas, reduced circulating sFas) supports a testable model linking the G allele to sFas and, in turn, organ failure in the critically ill. Because of some missingness in these cohorts, we were not able to perform a Mendelian randomization or mediation analysis to draw more direct causation. However, the associations resulted here provide support for this type of structured analysis of the Fas pathway in critical illness.

**CONCLUSIONS**

We have found that SNV rs982764-G located in intron 4-5 of FAS is associated with lower plasma sFas in two large critically ill cohorts. This SNV is also associated with decreased persistent systemic organ dysfunction. Finally, the G allele is associated with decreased relative expression of an mRNA isoform likely to code for sFas while also associated with increased cell surface expression of Fas on T cells. These findings provide evidence for a potential role of the Fas pathway in the development of organ failure in critical illness.

---

1. Translational Immunology, Benaroya Research Institute, Seattle, WA.
2. Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA.
3. Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN.
4. Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
5. Department of Epidemiology, Institute of Public Health Genetics, University of Washington, Seattle, WA.
6. Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, CA.
7. Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
8. Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
9. Harvard University School of Public Health and Division of Pulmonary and Critical Care, Department of Epidemiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Drs. Mikacenic and Wurfel contributed to study concept and design. All authors contributed to acquisition, analysis, or interpretation of data. Drs. Mikacenic, Bhatraju, Matthay, and Wurfel contributed to drafting of the article. All authors contributed to critical revision of the article for important intellectual content. Drs. Mikacenic, Bhatraju, and Robinson-Cohen contributed to statistical analysis. Drs. Mikacenic, Christiani, and Wurfel obtained funding. All authors contributed to administrative, technical, or material support: Drs. Christiani and Wurfel contributed to study supervision.

Supported, in part, by the National Institutes of Health: National Center for Advancing Translational Sciences UL1 TR002319, the National Heart, Lung, and Blood Institute (NHLBI) R01HL060710 and NHLBI RC2 HL101779, National Institute on Aging U19AG023122, NIAID AI101990, AI083455, and National Institute of Diabetes and Digestive and Kidney Issues DK097672.

Dr. Mikacenic’s institution received funding from the National Center for Advancing Translational Sciences (UL1 TR002319), the National Heart, Lung, and Blood Institute (NHLBI) (R01HL060710, RC2 HL101779), the National Institute on Aging (U19AG023122), the National Institute of Allergy and Infectious Diseases (AI101990, AI083455), and the National Institute of Diabetes and Digestive and Kidney Issues (DK097672). Drs. Mikacenic, Bhatraju, Robinson-Cohen, Long, Cerosaletti, Calfee, Matthay, Christie, Meyer, Christiani, and Wurfel received support for article research from the National Institutes of Health (NIH). Drs. Cerosaletti’s, Calfee’s, and Meyer’s institutions received funding from the NIH. Dr. Cerosaletti’s institution received funding from the Department of Defense, the American Diabetes Association, and the Juvenile Diabetes Research Foundation. Drs. Calfee’s and Matthay’s institutions received funding from Gentech/Roche. Dr. Calfee’s institution received funding from Bayer; she received funding from Quark, Vasovance, Genetec Life Sciences, and Prometic. Dr. Matthay received funding from Novartis and Cytis Pharmaceuticals. Dr. Russell received funding from Asahi Kasei Pharmaceuticals of America, IB Therapeutics LLC, and Ferring Pharmaceuticals; he received funding from Grifols; he disclosed that he is the inventor of two patents owned by the University of British Colombia and Ferring, that he is a founder, director, and shareholder in Cyon Therapeutics Inc and a shareholder in Molecular You Corp, and that he is a member of the Data Safety Monitoring Board of an NIH-sponsored trial of plasma in coronavirus disease 2019 (Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults [PassItOn]). Dr. Meyer’s institution received funding from the NHLBI (HL137006, HL137915), Quantum Leap Healthcare Collaborative, Biomarck, Inc, Athersys, Inc, and The Marcus Foundation. Dr. Wurfel’s institution received funding from the NHLBI. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: cmikacenic@benaroyaresearch.org

REFERENCES


